MXPA03004190A - Treatment of anxiety disorders. - Google Patents
Treatment of anxiety disorders.Info
- Publication number
- MXPA03004190A MXPA03004190A MXPA03004190A MXPA03004190A MXPA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A MX PA03004190 A MXPA03004190 A MX PA03004190A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- anxiety disorders
- anxiety
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24901000P | 2000-11-15 | 2000-11-15 | |
US26536201P | 2001-01-31 | 2001-01-31 | |
PCT/US2001/027801 WO2002040006A2 (en) | 2000-11-15 | 2001-11-06 | Treatment of anxiety disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03004190A true MXPA03004190A (en) | 2003-09-22 |
Family
ID=26939750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03004190A MXPA03004190A (en) | 2000-11-15 | 2001-11-06 | Treatment of anxiety disorders. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1395253A2 (en) |
JP (1) | JP2004529073A (en) |
KR (1) | KR20030051812A (en) |
CN (1) | CN1822825A (en) |
AU (1) | AU2002217757A1 (en) |
BR (1) | BR0115301A (en) |
CA (1) | CA2426069A1 (en) |
CZ (1) | CZ20031339A3 (en) |
EA (1) | EA200300567A1 (en) |
HR (1) | HRP20030384A2 (en) |
IL (1) | IL155874A0 (en) |
MX (1) | MXPA03004190A (en) |
NO (1) | NO20032156L (en) |
PL (1) | PL366119A1 (en) |
SK (1) | SK5422003A3 (en) |
WO (1) | WO2002040006A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL157779A0 (en) * | 2001-03-06 | 2004-03-28 | Lilly Co Eli | Inhibitor of monoamine uptake |
CN1674907A (en) * | 2002-08-14 | 2005-09-28 | 法玛西亚普强责任有限公司 | Use of reboxetine for the treatment of hot flashes |
GB0309440D0 (en) * | 2003-04-25 | 2003-06-04 | Lilly Co Eli | Quinolone derivatives |
WO2004103356A2 (en) * | 2003-05-15 | 2004-12-02 | Eli Lilly And Company | Treatment of emotional dysregulation |
KR20060121178A (en) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | Selective norephinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition |
EP2234960A2 (en) | 2008-01-09 | 2010-10-06 | Mayo Foundation for Medical Education and Research | Inhibiting neurotransmitter reuptake |
WO2011056773A2 (en) * | 2009-11-03 | 2011-05-12 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
WO2011056788A2 (en) * | 2009-11-03 | 2011-05-12 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
US9944618B2 (en) | 2013-03-14 | 2018-04-17 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
CN113710319A (en) * | 2019-02-01 | 2021-11-26 | 霍夫曼技术有限责任公司 | Compositions and methods for treating anxiety-related disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041878A1 (en) * | 1996-05-07 | 1997-11-13 | Merck & Co., Inc. | Treatment of mood disorders with a growth hormone secretagogue |
IT1305322B1 (en) * | 1998-04-23 | 2001-05-04 | Pharmacia & Upjohn Spa | Use of reboxetine for treating obsessive compulsive disorder and panic disorder |
PL196996B1 (en) * | 1999-07-01 | 2008-02-29 | Upjohn Co | Application of optically pure (S,S)-reboxetine and the pharmaceutically acceptable salts thereof for drug preparation |
-
2001
- 2001-11-06 BR BR0115301-3A patent/BR0115301A/en not_active IP Right Cessation
- 2001-11-06 PL PL01366119A patent/PL366119A1/en not_active Application Discontinuation
- 2001-11-06 EA EA200300567A patent/EA200300567A1/en unknown
- 2001-11-06 SK SK542-2003A patent/SK5422003A3/en not_active Application Discontinuation
- 2001-11-06 WO PCT/US2001/027801 patent/WO2002040006A2/en not_active Application Discontinuation
- 2001-11-06 CN CNA01818927XA patent/CN1822825A/en active Pending
- 2001-11-06 AU AU2002217757A patent/AU2002217757A1/en not_active Abandoned
- 2001-11-06 EP EP01996376A patent/EP1395253A2/en not_active Withdrawn
- 2001-11-06 KR KR10-2003-7006523A patent/KR20030051812A/en not_active Application Discontinuation
- 2001-11-06 CA CA002426069A patent/CA2426069A1/en not_active Abandoned
- 2001-11-06 MX MXPA03004190A patent/MXPA03004190A/en unknown
- 2001-11-06 JP JP2002542380A patent/JP2004529073A/en active Pending
- 2001-11-06 IL IL15587401A patent/IL155874A0/en unknown
- 2001-11-06 CZ CZ20031339A patent/CZ20031339A3/en unknown
-
2003
- 2003-05-13 NO NO20032156A patent/NO20032156L/en not_active Application Discontinuation
- 2003-05-14 HR HR20030384A patent/HRP20030384A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20032156D0 (en) | 2003-05-13 |
CN1822825A (en) | 2006-08-23 |
IL155874A0 (en) | 2003-12-23 |
BR0115301A (en) | 2004-12-14 |
NO20032156L (en) | 2003-05-13 |
EA200300567A1 (en) | 2004-10-28 |
EP1395253A2 (en) | 2004-03-10 |
CZ20031339A3 (en) | 2003-10-15 |
AU2002217757A1 (en) | 2002-05-27 |
JP2004529073A (en) | 2004-09-24 |
WO2002040006A2 (en) | 2002-05-23 |
PL366119A1 (en) | 2005-01-24 |
SK5422003A3 (en) | 2003-12-02 |
KR20030051812A (en) | 2003-06-25 |
HRP20030384A2 (en) | 2003-08-31 |
CA2426069A1 (en) | 2002-05-23 |
WO2002040006A3 (en) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0007193D0 (en) | Treatment of movrmrnt disorders | |
MXPA03007960A (en) | Compounds and methods for the treatment of urogenital disorders. | |
IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
IL159771A0 (en) | Combinations for the treatment of inflammatory disorders | |
HK1051690A1 (en) | Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain. | |
HK1053058A1 (en) | Use of pramipexole for the treatment of addictive disorders | |
HK1048069A1 (en) | Treatment of neurotic disorders. | |
AU9527001A (en) | Treatment of T cell disorders | |
MXPA03004190A (en) | Treatment of anxiety disorders. | |
HK1051692A1 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain. | |
ZA200205098B (en) | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. | |
HK1049122A1 (en) | The use of mirtazapine for the treatment of sleep disorders | |
IL140540A0 (en) | Treatment of anxiety disorders | |
MXPA03001472A (en) | Compounds for the treatment of addictive disorders. | |
SI1468686T1 (en) | S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders | |
AU4838301A (en) | Treatment of disorders relating to the serotonergic system | |
ZA200204018B (en) | Combination treatment for depression and anxiety. | |
GB0010496D0 (en) | Treatment of conditions of the central nervous system | |
IL153788A0 (en) | Treatment of eating disorders using carboxyalkylethers | |
GB0017951D0 (en) | Treatment of movement disorders | |
GB0003228D0 (en) | Treatment of GI disorders | |
GB0029955D0 (en) | Treatment of neuropsychiatric disorders | |
GB0004998D0 (en) | The treatment of functional gastrointestinal disorders | |
GB0021060D0 (en) | Treatment of functional gastrointestinal disorders | |
GB0125371D0 (en) | Treatment of movement disorders |